trending Market Intelligence /marketintelligence/en/news-insights/trending/v5fwyamd3bqc41ncpiytba2 content esgSubNav
In This List

Amicus Therapeutics director retires

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery


Amicus Therapeutics director retires

Amicus Therapeutics Inc. said Donald Hayden Jr. retired as a director.

The Cranbury, N.J.-based biotechnology company said Hayden had been on its board for 12 years.